ABSTRACT
INTRODUCTION
Sponsor investigator relationship is characterized by dealing with numerous sensitive tasks like trial management structure, required sponsor company qualities and various conflict of interest issues. Correct understanding of their distinct responsibilities as well as management of various possible controversies is essential for executing clinical trials successfully. Therefore, solicitude about the regulations concerning the sponsor and the investigator and their relationship is crucial. The introduction of the European Clinical Trials Directive (CTD) 2001/20/EC [1] and its national implementations, leading to the 12th amendment of the German Drug Law (AMG, Arzneimittelgesetz) in August 2004 [2] , have brought along a new legislative terminology and the necessitiy of a thorough distinction between the various kinds of sponsorship and investigatorship and associated trial forms. The CTD does not apply to non-interventional trials, where trial authorization is not required in most member states. The European Clinical Trials Directive and its incorporations into the member states legislative and regulative framework followed and were a result of the recommendations for Good Clinical Practice (GCP) of the International Conference on Harmonization (ICH) which was founded by the Food and Drug Administration (FDA), the European Medicines Agency (EMEA), the Japanese Ministry of Health, Labour and Welfare (MHLW), the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries and Associates (EFPIA) and the Japan Pharmaceutical Manufacturers Association (JPMA) in 1990.
RESPONSIBILITIES AND REQUIREMENTS OF SPONSORSHIP AND INVESTIGATORSHIP
A thorough knowledge and correct understanding of the relevant legal and regulatory framework is essential for adequate fulfillment of the various tasks of sponsorship and investigatorship, assurance of high quality standards, patient safety and successful completion of clinical trials. The increasing formal, legal and financial framework in the last decades directly resembled and had immediate impact on the complexity of the investigator-sponsor relationship and clinical trials conduct [3] .
To ensure a successful outcome, it is indispensable to achieve harmony of objectives and approaches through an ideally constructive professional relationship. Before the start of an investigational new drug clinical
GENERAL CHALLENGES OF SPONSOR-INVESTIGATOR-RELATIONSHIP
Clinical trials imply a number of specific regulatory requirements beyond those mandated for protection of human subjects in clinical research. These regulatory requirements for drug studies address the safety and efficacy issues unique to the use of pharmaceuticals in the clinical research setting. Failing to meet the regulations can have legal and financial implications for the individuals conducting the trials as well as the organizations related to the research activities. Of central importance is the Investigator's agreement, as sponsors may delegate investigative any or all duties to other persons and entities ( Table 3) .
Conflict of interests (COIs) can be defined as set of conditions, financial and non-financial, in which professsional judgment concerning a primary interest tends to be unduly influenced by a secondary interest [4] . It is obvious that conflicts of interest are common and inevi- Financing and compensation to subjects and investigators table in the academic field. The challenge is not to eradicate them, but to recognize them and manage them properly. The only acceptable way to do this is by full disclosure and involvement of all participants, namely the research subject, the researcher, the institution where the research is taken place, the sponsor, the ethics committee, the regulating agencies, the scientific community and society. Regulatory bodies, scientific journals and institutions set up various guidelines and thresholds for disclosure in the past. However, confusion and concern about the resolution of conflicting evidence exists. There is agreement on the necessity of declaring COIs, but there is no agreement on what constitutes a permissible degree of COI. At a maximum the investigator has to abandon either the research interest or proprietary interest to avoid running afoul of regulatory requirements and incurring serious litigation and public relations risks. Also, the important matter of complete reporting of data remains incompletely addressed. The Association of American Medical Colleges (AAMC) emphasizes the fact that institutional financial interests, as much as those of an individual investigator, may threaten a study. It Table 3 . Challenges of sponsor-investigator-relationship.
General challenges
Variabile responsibility in different countries of trial approval and notification to the CAs/Ecs National differences in timelines of applications, adverse event reporting, data storing goes well beyond the requirement for full financial disclosure of investigators and recommend that individuals who hold a financial interest in a particular area of research should not be involved in clinical research in that area [5] .
Criteria for data ownership and access, data design, collection and analysis (including outside analysis) are common claims a long time to adequately manage the reasons for publication bias [6] , which clearly extends to non-commercial research [7] . Besides, data ownership issues start to play a distinctive role inside definitions of non-commercial sponsors. In the US, the Department of Health and Human Services recommends that responsibilities involving design of the study and analysis of the results should be shared between a sponsor and investigators in order to prevent potential influence of financial relationships on the outcome of the trial [8] . The International Committee of Medical Journal Editors (ICMJE) has set guidelines of sponsored research regarding authors' access to data, integrity of data, accuracy of data analysis, authors publishing rights and trial registration in a data base to qualify for publication [9] . The majority of quality general medicinal journals require disclosure of the role of the sponsor and a written assurance that the investigators accept full responsibility for the conduct of the study, have had access to all the data and had the authority to publish it. In addition, these guidelines require editors to verify (if necessary, by inspecting research contracts and study protocols) that researchers had full access to all study data and that there were no restrictions on publication [10] .
Concerns about bias, research fraud and the ethics of clinical trials can be addressed by truly independent and properly constituted data and safety monitoring boards (DSMBs). The DSMB is an independent group of clinicians and statisticians and meets periodically to review the unblinded data that the sponsor has received so far. The DMSB has the power to recommend termination of the study based on their review, for example if the study treatment is causing more deaths than the standard treatment, or seems to be causing unexpected and study-related serious adverse events. Truly independent and properly constituted data and safety monitoring boards are of particular importance when academic investigators or universities have a large financial conflict. The National Institutes of Health (NIH) requires a Data Safety Monitoring Board (DSMB) for all Phase III trials and a safety monitoring plan for Phase I and II trials. The FDA issued in 2006 guidance for clinical trial sponsors for the establishment and operation of clinical trials monitoring committees [11] . The FDA requires a DSMB for long-term trials with mortality or major morbidity outcome measures, when serious adverse events (SAE) are expected, with novel and/or potentially high-risk treatments, when very little prior information about the study treatment is available, when studying an at-risk population consisting of vulnerable subjects (e.g., elderly or paediatric patients) or with a multicenter or longterm study. Conversely, an external DSMB is not required in early phase trials (with the exemption of gene therapy trials), trials with symptom-only endpoints, and short-term trials.
In the last decade, numerous studies addressed the problems of selective data presentation [12] [13] [14] , data suppression, named authorship and that industry-sponsored trials report less often negative outcomes than independent studies. Positive and significant results are more often published than negative and insignificant results [15] [16] [17] and in the past only 25% -50% of approval studies were published according to comparisons with FDA data [18] . Consequently, there have been numerous calls for publicly available study protocols and results, as industrial financing tends to affect study procedures, results and publication in multiple ways which cannot be explained by methodological study quality [19, 20] . In this context, the new trial databases and the initiatives of publishers of medical journals addressed and tried to set guidelines to ensure high-standard publication. In contrast to Europe, in the USA all clinical trials have to be registered in a database with free public ac-cess. In Europe this is not legally enforced but due to an initiative. In addition, in the USA study publication became mandatory in 2008 [21, 22] . The passage of Title VIII (Section 801) of the FDA Amendment Act (FDAAA) of 2007, made it federal law to register most intervenetional clinical trials at outset and to disclose trial results (for marketed products) by twelve months after study completion [23, 24] . There exists general agreement by the industry to make clinical trial results public [25] . Besides PhRMA recently extended its policy to go beyond the current FDAAA requirements, calling on its members to register and disclose results of all studies involving patients for all products marketed and those investigational products whose development has been discontinued [26] .
Due to increased regulation and legislation in the last decades bringing along higher research costs and slower patient recruitment, many research-based companies seek to outsource some of their trials to Third World countries with less stringent regulation like China, India, Indonesia or Thailand. Nevertheless, the laws and regulations might differ in substantial manner. Sponsors and investigators must deal with multiple legal jurisdictions, with different laws regulations and other rules and has to understand regional differences. Consequently, the sponsor often needs to fall back on local resources and contract research organizations (CROs). In India for example, which is a particularly attractive site for clinical research due to its genetically diverse population, sponsors do not have exclusive rights to the clinical data they generate, as trial reports are in the public domain. Consequently, manufacturers of generic drugs can use the data to get regulatory approval for their own versions of drugs. China has a long regulatory clinical trial approval process, which may take up to one year, minimum 195 days to review an application for a multinational study [27] . Intellectual property rights are only sporadic enforced. In contrast, Latin American countries like Argentina, Brazil and Mexico generally comply with ICH guidelines. Violation of Western standards might be the ground for liability claims in Western and Third World countries in a jointly manner. The Abdullahi vs. Pfizer Case underlines the need to ensure that a company conducting clinical trials in Third World Countries keeps regulatory and ethical requirements. In this case an US sponsor who conducted a clinical trial in Nigeria was sued under the Alien Tort Statue [28] , which allows United States courts to hear human rights cases brought by foreign citizens for conduct committed outside the United States. co-sponsorship-two or more organizations take ultimate responsibility for discrete sponsor responsibilities; e.g. one organisation is responsible for GCP and conduct the other for pharmacovigilance and the third for authorisation and EC opinion [30] . The implementation of the European CTD into national law lead to various regulatory differences in the EU member states (MS). Significant differences exist in insurance coverage and liability issues throughout Europe. Patients are EU-wide covered by the trial insurance, but differences remained in place regarding the amounts (total and individual per trial) specified by each MS. Due to its complicated nature it is obvious that different countries handle the compensation to the injured research patient differently, including the extent and duration of coverage and the assignment of responsibility for paying compensation, the kind of compensable injuries including death, serious harm pain suffering and economic losses, the compensability of harms and of health problems which are inevitable in a trial. The nature of the insurance is optional according to US federal regulations and compulsory in Europe [31] . Different interprettations of the European CTD lead to various regulatory differences in the MS making multinational trials more difficult. The timelines for Competent Authority (CA) or Ethics Committee (EC) approval, adverse event reporting or retention of study records differ in the MS. In Spain and France missing response by the CA means approval. Information of any urgent safety measure to the CA or EC is required in Germany and Belgium immediately, in England within three days. Most MS require immediate reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs). In France a declaration SUSARs to the the CA and EC is required every six months. In France, UK and Sweden it is possible to appeal against negative EC decision. Besides, Germany and Italy have not established a national ethics review committee. Both countries continue to have regional ethics boards. Researchers must apply to each local jurisdiction where a proposed trial takes place.
CHALLENGES OF THE EUROPEAN CLINICAL TRIALS DIRECTIVE
The European CTD does not address procedures in patients who are unable to give informed consent. Research in populations with difficulties to get informed consent, e.g. emergency medicine psychiatry, neurology, has been impacted due to variable and often restrictive consenting procedures for incapacitated subjects, with some countries requiring a court-appointed representative, while others recognise consent from family members and occasionally professional representatives [32] . In this context, regulations for strict risk/benefit analysis, involvement of ECs, relatives and request procedures for informed consent subsequently are necessary.
FIRST EXPERIENCES WITH THE EUROPEAN CLINICAL TRIALS DIRECTIVE
So far, there is no simplification or acceleration of administrative processes contrasting the goal of facilitating faster access to novel therapies through harmonization of administrative regulatory requirements and defining binding timelines for the review and approval processes. Concern of delays of 4 to 11 months before trial initiation of cancer studies were expressed [33] .
Since the implementation of the ICH-GCP, sponsors are not only responsible for initiation but also for the management of clinical trials. It was reported that the initial response for clinical trials to the implementation of the ICH-GCP guideline were clinical trial price increases and a decrease in the number of study contracts [34] . Similar developments were assumed and feared for the implementations of the European CTD. Because registers and statistics about clinical trials were not routinely maintained in the past, every estimation on the quantitative impact of the CTD 2001/20/EC on the number of trials remains rudimentary. A perceived reduction of commercial and non-commercial trials was described by numerous authors. [36] .
In Finland, the number of approved applications in surgery and oncology trials decreased by 42%, from 120 in 2002 to 70 in 2005. Academic drug trials decreased from 20 to 5 between 2003 and 2005. Nevertheless, the workload of the ethics committees and competent authorities increased [37] .
The national implementation of the European Clinical Trial Directive has profoundly changed the face of clinical research. Since the regulatory framework is focused much more on commercial trials and does not address facilities for the conduct of non-commercial trials beyond labeling issues, concerns have been expressed that non-commercial research projects will be reduced and the vital medical research conducted at academic institutions curtailed. One of the chief reasons behind the concerns was the increased bureaucracy and related required paperwork for monitoring and auditing processes. It was stressed out that it has to be possible to fulfill the bureaucracy of the trials in the daily care setting to avoid bias introduction. Another concern was that it would be too onerous for public institutions with limited resources. One editorial published in The Lancet went so far to ask if the European CTD would be the death of academic clinical trials [38] . The first numbers confirmed the worries about the future of investigator initiated clinical trials. A study published in the British Medical Journal in August 2008 concluded that for Denmark, there was no decreasement in non-commercial trials after implementation of the European CTD, however a decline since 1993 could be shown; may be as a result of the introduction of the GCP guidelines. However, in Denmark the underlying circumstances for non-commercial research are quite outstanding compared with other MS as universities and university hospitals fund good clinical practice units that provide free assistance to academic clinical researchers [39] . In contrast, a report from Austria based on data of an University hospital mentioned a decrease of non-commercial trials of 66%. There was no decline in industry-sponsored trials [40] . Prior to the directive, academic-sponsored clinical trials in the United Kingdom required approval only from the EC. According to figures from the Medicines and Healthcare Products Regulatory Agency 1085 clinical trials were carried out in the UK in 2005 compared with 1252 in 2008 [41] . Consequently, it can be concluded that there is no causal relationship between reduced numbers of non-commercial clinical trials and the EU CTD. However, there is a need for adequate resource allocation, environmental setting and financial circumstances. In this relationship, not each country can handle this so that a need for clear regulations for non-commercial trials regarding specific alleviations for academic research exists. In this relationship, the GCP-Directive 2005 gives member states more flexibility, to rule investigator-initiated trials as it states that the conditions under which the non-commercial research is conducted by public researchers and the places where this research takes place, make the application of certain of the details of good clinical practice unnecessary or guaranteed by other means [42] . The Directive simplifies requirements for manufacturing, importation and labeling of investigational medical products (IMPs) in non-commercial trials.
FUTURE TRENDS OF SPONSOR-INVESTIGATOR-RELATIONSHIP AND THE EUROPEAN CLINICAL TRIALS DIRECTIVE
The above mentioned controversies, deficiences and challenges lead to numerous ongoing initiatives and discussions among academics, industry, patient organizations and regulatory bodies. Multiple initiatives to address the deficiencies and refine the European CTD were set up. Their results of discussion should be summarized in the following.
The [45] . Consequently, in the last years, there were numerous initiatives on national, regional, institutional and private level for educational, administrative, funding and legal support to set-up clinical trials on multiple levels, European, national, institutional and scientific or investigator-driven, as summarized in Table 5 Initiatives for non-commercial trial support since implementation of the European Clinical Trial Directive 2001/20/EC. As a consequence EU-wide infrastructure networks and disease-oriented scientific networks were set up or existing networks were reinforced to overcome these obstacles [46, 47] . Bergmann et al. suggested an expanded role for expert organizations like the EORTC. They could provide a forum for academics and industry to plan within a regulatory framework and work closely with the regulatory authorities and legislative bodies [48] . EORTC already coordinates multicenter trials. Other authors called for a network of centers of excellence in clinical research in Europe, where clinical trials should be referred to and conducted [49] .
Investigator-driven trials often deal with potential diagnostic and therapeutic innovations that do not attract commercial interests, e.g. proof of concept studies, studies on orphan diseases, comparison of diagnostic or therapeutic interventions, surgical therapies or novel indications for registered drugs. Very few public entities (universities hospitals, funding bodies, charitable or- Calls for expanded role for expert organizations like the EORTC which already coordinate multicenter trials, as they could provide a forum for academics and industry to plan within a regulatory framework and work closely with the regulatory authorities and legislative bodies Calls for Academic Research Organizations (AROs) allocated at the universities which provide almost all services that are required from a commercial sponsor Calls for clinical trial networks of universities and hospitals similar to the USA which receive with from both industry and NIH ganizations) had the necessary infrastructure to handle the increased administrative and legal requirements. Funding was usually insufficient to pay for the increased administrative costs. In this context, the Guidance document on specific modalities for non-commercial trials mentions in recital 11 of the 2005/28/EC Directive states that the data from non-commercial trials cannot be used for registration [50] , which is a major obstacle to academic-sponsored research and to the development of new indications for marketed medicines, especially in rare diseases.
Consequently, it exists a need for further definition and facilitations for non-commercial trials across the MS. A waiver-system for non-commercial trials and a waiver for the sponsor to purchase the IMP in non-commercial trials or harmonizing and providing uniform models for insurance coverage and liability for non-commercial trials by the public health system, by the public hospitals or by the university hospitals might constitute mile stones in this direction. For example, in Belgium the sponsor of a non-commercial trial does not file certain quality data with the government authority when applying for authorization in respect of a previously registered drug, does not have to pay any ethics committee fees and may be excused from certain labelling requirements [51] . In Italy 5% of marketing expenses have to be paid to the Italian Medicines Agency (AIFA) for financing non-commercial trials, e.g. longterm studies and side-effect studies as the EU CTD focuses on efficacy testing [52] .
CONCLUSIONS
A thorough knowledge and correct understanding of the relevant legal and regulatory framework is essential for adequate fulfillment of the various tasks of sponsorship and investigatorship, assurance of high quality standards, patient safety and successful completion of clinical trials. In this context, the European Clinical Trials Directive 2001/20/EC and its subsequent different national implementations set landmarks in regards of quality assurance and patient safety. On the other hand, the regulatory framework focuses on commercial trials and does not facilitate the conduct of non-commercial trials. It brought along enhanced liability issues, insurance conditions, administrative requirements, documentation and monitoring standards. Hence, it raised various practical and financial concerns for non-commercial trials. A perceived reduction of commercial and non-commercial trials was the result. In the last years, there were numerous initiatives on national, regional, institutional and private level for educational, administrative, funding and legal support to set-up clinical trials. But the regulatory framework still left open legal questions which need to be answered by the competent authorities, e.g. guidelines for co-sponsorship are still missing.
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